Shots:
- The US FDA has approved Susvimo (port delivery platform with Lucentis) for the treatment of diabetic retinopathy (DR)
- Approval was based on 1 yr. P-III (Pavilion) trial data assessing Susvimo (100mg/mL, refilled Q9M) vs monthly clinical observation in 173 pts with non-proliferative DR without center-involved DME, where subjects in Susvimo arm received 2 loading doses of intravitreal Lucentis prior to implantation at Wk. 4
- Trial showed superior DRSS improvements, demonstrating reduced eye damage caused by diabetes without the need of a supplemental treatment at 1yr.
Ref: Globenewswire| Image: Roche| Press Release
Related News:- Roche Launches Elecsys PRO-C3 Test for Liver Fibrosis Severity Assessment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
